Weakness in tools such as ILMN ($59.30) down 15% is hurting biotech. Also our mid cap biopharma index is down 2.5% . So the NASDAQ-100 is favored due to the inclusion of AAPL, AMZN, INTC and MSFT etc and larger cap biotech stocks.
- Groups sue over Alabama abortion law; judge blocks Mississippi ban May 25, 2019
- Mexico budget cuts hit patient care and delay kids' surgeries, doctors warn May 24, 2019
- Novartis $2 million gene therapy for rare disorder is world's most expensive drug May 24, 2019
- Doctor, medical funder charged in New York in transvaginal mesh fraud May 24, 2019
2009-2017 Life Science Portfolios 2018 Rayno Biopharmaceuticals Portfolio 2018 Rayno Tools and Diagnostics Portfolio BIOgraph Biopharmaceuticals Clinical Diagnostics and Tools Energy Life Science ETF's and Mutual Funds Macro RAG Rayno Life Science Portfolio Reading List Weather//Ski Reports-Western US Weather Snow Reports West Coast